The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets thought to protect ...

Solnerstotug showed a 14% response rate and 62% disease control in PD-L1 resistant tumors, surpassing typical expectations. Significant responses were observed in Merkel cell carcinoma and ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

The use of Trodelvy plus Keytruda in patients with previously untreated PD-L1+ metastatic TNBC is investigational, and the safety and efficacy of this use have not been established. The ...